Tag: Drug

07
Oct
2020
Posted in seo

Addiction Treatment Marketing And Rehab Marketing By The Drug Rehab Agency Through SEO, Paid Search, and More – Press Release

Since 2014, The Drug Rehab Agency has been helping addiction recovery centers and rehab clinics reach out to their target audience online through tried and tested digital marketing techniques. These include SEO, content marketing, PPC, radio, television, etc.

FORT COLLINS, CO / ACCESSWIRE / October 7, 2020 / According to announcements released by The Drug Rehab Agency and Marcus Hansen, this addiction treatment marketing agency helps addiction rehab clinics get in touch with patients in need of their services through online and offline marketing campaigns. The agency has helped addiction recovery centers reach the top of the SERPs for highly competitive keywords and benefit from organic traffic.

It has the expertise and domain knowledge to help smaller clinics compete with the more prominent players in this sector. With proven strategies that work, the rehab marketing agency can create customized marketing plans that consider factors such as the intended audience’s location, type of service offered, budget, etc. Its offerings are of particular value for startups that wish to settle down quickly, engage with a responsive audience, and generate revenue without committing mistakes that new rehab centers commonly make.

The Drug Rehab Agency adopts a holistic approach to market the services of a rehab facility; this means that clients can expect the best returns on their marketing investments. With a thorough knowledge of the best practices related to the different aspects of digital marketing and the experience in adapting such practices for this particular niche, the agency enables addiction recovery clinics to develop a solid foundation for sustained growth and creating a reputation as the go-to clinic in a targeted area for addiction recovery. It also helps new drug and alcohol recovery centers through its substance abuse billing services that ensure timely payments from insurance providers.

For more information, go to https://www.drugrehab.agency/

05
Oct
2020
Posted in technology

Nvidia Partners With GlaxoSmithKline to Use AI for Drug Development

Nvidia  (NVDA) – Get Report said Monday it was partnering with GlaxoSmithKline  (GSK) – Get Report and its artificial intelligence group to use AI for developing new drugs and vaccines, while building a supercomputer to aid researchers in their work on the coronavirus and other challenges.

Shares of Nvidia, the Santa Clara, Calif.-based computer graphics chip company, were up 3.4% to $540.08, while American depositary receipts of GlaxoSmithKline rose 1.5% to $37.79. 

Located in London, GSK’s hub will use biomedical data, AI methods and advanced computing platforms to unlock genetic and clinical data, Nvidia said.

The GSK AI hub will be home to its U.K.-based AI team, including GSK AI Fellows, a new professional training program and now scientists from Nvidia.

“GSK and Nvidia together will help push the boundaries of what AI can do and put vast data sources to work to advance the discovery of new medicines and vaccines,” Kimberly Powell, vice president of healthcare at Nvidia, said in a statement.

In addition, Nvidia said it was building what it called the United Kingdom’s most powerful supercomputer, which it will make available to U.K. healthcare researchers using AI to solve pressing medical challenges, including those presented by Covid-19.

The “Cambridge-1” computer is expected to come online by year-end.

GSK and AstraZeneca will be among the first pharmaceutical companies to use Cambridge-1 for research.

The computer will be a Nvidia DGX SuperPOD system capable of delivering more than 400 petaflops of AI performance. It will rank among the world’s top 3 most energy-efficient supercomputers on the current Green500 list.

Last month, Nvidia reached an agreement to acquire Arm Holdings from the British chip designer’s Japanese parent SoftBank for $40 billion.

04
Oct
2020
Posted in software

Worldwide Drug Modeling Software Industry to 2027 – Increasing Adoption of Modelling Tools in Drug Discovery is Driving Growth

DUBLIN, Oct. 2, 2020 /PRNewswire/ — The “Drug Modeling Software Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product type; Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.

According to this report the global drug modeling software biopharmaceutical market is expected to reach US$ 11,299.85 million by 2027 from US$ 6,205.22 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The report highlights the trends prevalent in the global drug modeling software market, and the drivers and deterrents pertaining to its growth.

Based on product type, the drug modeling software market is segmented into database, software, and others. In terms of product type, the software segment held the highest share of the drug modeling software market in 2019 and is estimated to register the highest CAGR of 8.4% in the market during the forecast period. The growth of the market is attributed to the growing demand for effective therapeutics and increasing number of drug discovery efforts of various biologics across a wide range of therapeutics. Additionally, strategic activities by service providers such as collaborations, product advancement, and product launch in order to expedite drug discovery timeline are further accelerating the growth of the market.

The market growth is also attributed to a few key factors such as increasing adoption of in-silico modeling tools in drug discovery, and rising economic burden of drug discovery. However, less adoption in emerging countries is expected to hamper the growth of the market up to certain extent during the forecast period.

Crown Bioscience Inc.; Chemical Computing Group Ulc; Nimbus Therapeutics; Schrdinger, Inc.; Dassault Systmes; Genedata Ag; Biognos Ab; Compugen Ltd; Acellera ltd.; and Leadscope, Inc plc are among the prominent players operating in the drug modeling software market. The market players

04
Oct
2020
Posted in technology

India and South Africa ask WTO to waive rules to aid COVID-19 drug production

FILE PHOTO: A logo is pictured outside the World Trade Organization (WTO) headquarters next to a red traffic light in Geneva, Switzerland, October 2, 2018. REUTERS/Denis Balibouse/File Photo

VIENNA (Reuters) – India and South Africa want the World Trade Organization (WTO) to waive intellectual property rules to make it easier for developing countries to produce or import COVID-19 drugs, a letter here&Open=True to the WTO shows.

In their letter dated Oct. 2 the two countries called on the global trade body to waive parts of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which governs patents, trademarks, copyright and other intellectual property rules globally.

“As new diagnostics, therapeutics and vaccines for COVID-19 are developed, there are significant concerns (over) how these will be made available promptly, in sufficient quantities and at (an) affordable price to meet global demand,” the letter posted on the Geneva-based WTO’s website says.

The two countries said that developing nations are disproportionately affected by the pandemic and that intellectual property rights, including patents, could be a barrier to the provision of affordable medicine.

The letter asks that the WTO’s Council for TRIPS recommends a waiver to the General Council, the WTO’s top decision-making body in Geneva, “as early as possible”. It does not say how much support India and South Africa have from other countries.

A draft General Council decision text submitted with the letter says the waiver should last an as yet unspecified number of years and be reviewed annually.

Reporting by Francois Murphy; Editing by David Goodman

Source Article

01
Oct
2020
Posted in software

Food and Drug Administration Renews and Expands Use of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

FDA’s Office of Pharmaceutical Quality adds new licenses of Simcyp Simulator

Certara, a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has again renewed and expanded its licenses of Certara’s biosimulation software, with more than 400 user licenses of Simcyp™ and Phoenix™ platforms. Eleven divisions and offices of the FDA use Certara’s software for internal research and to independently analyze, verify, and review regulatory submissions.

Certara’s Simcyp Simulator, an industry-leading platform for physiologically-based pharmacokinetic (PBPK) modeling and simulation, is used to determine first-in-human dose, design more efficient and effective clinical studies, and predict drug-drug interactions using virtual populations. The FDA’s Office of Clinical Pharmacology has renewed its licenses for the Simcyp Simulator, including Simcyp Pediatric and the Simcyp Cardiac Safety Simulator. Furthermore, the FDA’s Office of Pharmaceutical Quality recently ordered Simcyp user licenses, expanding the FDA’s use of the platform. The agency uses Simcyp software to independently analyze, verify, and review sponsor IND, BLA, NDA, ANDA, and other submissions.

“Regulators around the world rely on our sophisticated software to inform their reviews of regulatory submissions,” said Rob Aspbury, Ph.D., president of the Simcyp division at Certara. “It is a privilege to continue partnering with the FDA to demonstrate the ever-increasing uses of PBPK modeling to optimize drug development and support the regulatory review process in an effort to bring safe and efficacious therapies to market.”

Additionally, the FDA has renewed its user licenses of Certara’s Phoenix Platform, a comprehensive and widely-used software for pharmacokinetic, pharmacodynamic, and toxicokinetic modeling and simulation. Eleven divisions and offices at the FDA, along with ten other global regulatory agencies such as Japan’s Pharmaceuticals and Medical Devices Agency and China’s National Medical Products Administration, use the Phoenix Platform to evaluate regulatory submissions.

Certara’s customers use Phoenix extensively